The Journal of Medical Microbiology, Vol 43, Issue 5 335-343, Copyright © 1995 by Society for General Microbiology

JOURNAL ARTICLE

Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease

I. Idanpaan-Heikkila, E. A. Hoiby, P. Chattopadhyay, U. Airaksinen, T. M. Michaelsen and E. Wedege
Department of Bacterial Vaccine Research and Molecular Bacteriology, National Public Health Institute, Helsinki, Finland.

Antibodies to the meningococcal serosubtype-specific P1.7,16 protein and its variable regions (VR) were analysed in 28 convalescent sera drawn 8-36 months after systemic meningococcal disease by immunoblotting and enzyme immunoassay (EIA) methods. EIA antigens were the meningococcal P1.7,16 protein, produced in Bacillus subtilis, and peptides covering its VR1 (P1.7 region) and VR2 (P1.16 region) inserted into a bacterial penicillinase protein. In the immunoblotting method, three meningococcal reference strains were used; they expressed either the P1.7,16 protein, or only its VR1 or VR2 epitopes in their class 1 proteins. Both methods showed a strong IgG response in four sera to P1.7,16 and VR2, but not to VR1; 18 sera had no or weak anti-class 1 protein activity. The six remaining sera were positive only on blots. The VR2-specific sera had 30-fold higher bactericidal activity than those with negligible P1.7,16 responses. Previous vaccination of the patients with a B:15:P1.7,16 meningococcal vaccine was associated with a strong anti-P1.7,16 and anti-VR2 booster response that declined with time. The subtype-specific antibody activity in some sera indicated colonisation after disease by meningococci with class 1 proteins different from the strain that had caused disease.

This article has been cited by other articles:

				E. Wedege, K. Bolstad, A. Aase, T. K. Herstad, L. McCallum, E. Rosenqvist, P. Oster, and D. Martin Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines Clin. Vaccine Immunol., July 1, 2007; 14(7): 830 - 838. [Abstract] [Full Text] [PDF]

				D. R. Martin, N. Ruijne, L. McCallum, J. O'Hallahan, and P. Oster The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB Clin. Vaccine Immunol., April 1, 2006; 13(4): 486 - 491. [Abstract] [Full Text] [PDF]

				L. H. Harrison Prospects for Vaccine Prevention of Meningococcal Infection Clin. Microbiol. Rev., January 1, 2006; 19(1): 142 - 164. [Abstract] [Full Text] [PDF]

				E. Wedege, B. Kuipers, K. Bolstad, H. van Dijken, L. O. Froholm, C. Vermont, D. A. Caugant, and G. van den Dobbelsteen Antibody Specificities and Effect of Meningococcal Carriage in Icelandic Teenagers Receiving the Norwegian Serogroup B Outer Membrane Vesicle Vaccine Infect. Immun., July 1, 2003; 71(7): 3775 - 3781. [Abstract] [Full Text] [PDF]

				A. J. Pollard, R. Galassini, E. M. Rouppe van der Voort, R. Booy, P. Langford, S. Nadel, C. Ison, J. S. Kroll, J. Poolman, and M. Levin Humoral Immune Responses to Neisseria meningitidis in Children Infect. Immun., May 1, 1999; 67(5): 2441 - 2451. [Abstract] [Full Text] [PDF]

				J. W. Tappero, R. Lagos, A. Maldonado Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, et al. Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines: A Randomized Controlled Trial in Chile JAMA, April 28, 1999; 281(16): 1520 - 1527. [Abstract] [Full Text] [PDF]

				L. G. Milagres, M. C. A. Gorla, C. T. Sacchi, and M. M. Rodrigues Specificity of Bactericidal Antibody Response to Serogroup B Meningococcal Strains in Brazilian Children after Immunization with an Outer Membrane Vaccine Infect. Immun., October 1, 1998; 66(10): 4755 - 4761. [Abstract] [Full Text] [PDF]

				E. Wedege, E. A. Hoiby, E. Rosenqvist, and G. Bjune Immune Responses against Major Outer Membrane Antigens of Neisseria meningitidis in Vaccinees and Controls Who Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trial Infect. Immun., July 1, 1998; 66(7): 3223 - 3231. [Abstract] [Full Text] [PDF]